SPRO Stock Overview
A clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Spero Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.19 |
| 52 Week High | US$1.89 |
| 52 Week Low | US$1.01 |
| Beta | 0.63 |
| 11 Month Change | -6.30% |
| 3 Month Change | -13.14% |
| 1 Year Change | -1.65% |
| 33 Year Change | -92.56% |
| 5 Year Change | -89.92% |
| Change since IPO | -89.65% |
Recent News & Updates
Recent updates
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding
Nov 02
Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
Jul 15Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Apr 23Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 12Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jan 02Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
May 18Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Apr 17Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Apr 13We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
Oct 03Spero Therapeutics appoints Kamal Hamed MD CMO
Sep 15Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
Sep 06Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Aug 10We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate
Jul 04We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely
Mar 17Shareholder Returns
| SPRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.8% | -6.5% | -1.0% |
| 1Y | -1.7% | 14.6% | 30.3% |
Return vs Industry: SPRO underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: SPRO underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| SPRO volatility | |
|---|---|
| SPRO Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SPRO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SPRO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 46 | Sath Shukla | sperotherapeutics.com |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd.
Spero Therapeutics, Inc. Fundamentals Summary
| SPRO fundamental statistics | |
|---|---|
| Market cap | US$65.42m |
| Earnings (TTM) | US$3.51m |
| Revenue (TTM) | US$106.46m |
18.5x
P/E Ratio0.6x
P/S RatioIs SPRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRO income statement (TTM) | |
|---|---|
| Revenue | US$106.46m |
| Cost of Revenue | US$51.44m |
| Gross Profit | US$55.02m |
| Other Expenses | US$51.50m |
| Earnings | US$3.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.064 |
| Gross Margin | 51.68% |
| Net Profit Margin | 3.30% |
| Debt/Equity Ratio | 0% |
How did SPRO perform over the long term?
See historical performance and comparison